Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: The EURODIAB Prospective Complications Study

Stijn A. Peeters, Lian Engelen, Jacqueline Buijs, Nish Chaturvedi, John H. Fuller, Casper G. Schalkwijk, Coen D. Stehouwer, B. Karamanos, A. Kofinis, K. Petrou, F. Giorgino, G. Picca, A. Angarano, Pergola G. de, L. Laviola, R. Giorgino, C. Ionescu-Tirgoviste, A. Coszma, C. Guja, M. SonginiA. Casu, M. Pedron, S. Pintus, M. Fossarello, J. B. Ferriss, G. Grealy, D. O'Keefe, M. Toeller, C. Arden, R. Rottiers, C. Tuyttens, H. Priem, P. Ebeling, M. Kylliainen, V. A. Koivisto, B. Idzior-Walus, J. Sieradzki, K. Cyganek, B. Solnica, H. H P J Lemkes, J. C. Lemkes-Stuffken, J. Nunes-Correa, M. C. Rogado, L. Gardete-Correia, M. C. Cardoso, A. Silva, J. Boavida, M. Machado Sa Marques, G. Michel, R. Wirion, S. Cardillo, G. Pozza, R. Mangili, V. Asnaghi, E. Standl, B. Schaffler, H. Brand, A. Harms, M. Ben Soussan, O. Verier-Mine, P. Fallas, M. C. Fallas, J. H. Fuller, J. Holloway, L. Asbury, D. J. Betteridge, G. Cathelineau, A. Bouallouche, B. Villatte Cathelineau, F. Santeusanio, G. Rosi, V. D'Alessandro, C. Cagini, P. Bottini, G. P. Reboldi, R. Navalesi, G. Penno, S. Bandinelli, R. Miccoli, M. Nannipieri, G. Ghirlanda, C. Saponara, P. Cotroneo, A. Manto, A. Minnella, J. D. Ward, S. Tesfaye, S. Eaton, C. Mody, M. Borra, P. Cavallo Perin, S. Giunti, G. Grassi, G. F. Pagano, M. Porta, R. Sivieri, F. Vitelli, M. Veglio, N. Papazoglou, G. Manes, M. Muggeo, M. Iagulli, V. Cacciatori, V. Cattedra di Malattie del Metabolismo, K. Irsigler, H. Abrahamian, S. Walford, J. Sinclair, S. Hughes, V. McLelland, J. Ward, G. Roglic, Z. Metelko, Z. R. Pepeonik

Research output: Contribution to journalArticlepeer-review

Abstract

Impaired regulation of extracellular matrix remodeling by matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase (TIMP) may contribute to vascular complications in patients with type 1 diabetes. We investigated associations between plasma MMP-1, -2, -3, -9, -10 and TIMP-1, and cardiovascular disease (CVD) or microvascular complications in type 1 diabetic patients. We also evaluated to which extent these associations could be explained by low-grade inflammation (LGI) or endothelial dysfunction (ED). Methods: 493 type 1 diabetes patients (39.5 ± 9.9 years old, 51% men) from the EURODIAB Prospective Complications Study were included. Linear regression analysis was applied to investigate differences in plasma levels of MMP-1, -2, -3, -9, -10, and TIMP-1 between patients with and without CVD, albuminuria or retinopathy. All analyses were adjusted for age, sex, duration of diabetes, Hba1c and additionally for other cardiovascular risk factors including LGI and ED. Results: Patients with CVD (n = 118) showed significantly higher levels of TIMP-1 [β = 0.32 SD (95%CI: 0.12; 0.52)], but not of MMPs, than patients without CVD (n = 375). Higher plasma levels of MMP-2, MMP-3, MMP-10 and TIMP-1 were associated with higher levels of albuminuria (p-trends were 0.028, 0.004, 0.005 and 0.001, respectively). Severity of retinopathy was significantly associated with higher levels of MMP-2 (p-trend = 0.017). These associations remained significant after further adjustment for markers of LGI and ED. Conclusions: These data support the hypothesis that impaired regulation of matrix remodeling by actions of MMP-2, -3 and-10 and TIMP-1 contributes to the pathogenesis of vascular complications in type 1 diabetes.

Original languageEnglish
Article number31
JournalCardiovascular Diabetology
Volume14
Issue number1
DOIs
Publication statusPublished - Mar 10 2015

Keywords

  • Albuminuria
  • Cardiovascular disease
  • Matrix metalloproteinase
  • Retinopathy
  • Tissue inhibitor of metalloproteinase
  • Type 1 diabetes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism

Fingerprint

Dive into the research topics of 'Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: The EURODIAB Prospective Complications Study'. Together they form a unique fingerprint.

Cite this